Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K20 | Q9NYL2 | 11/20 | 1.00 |
| ▸ | BRAF | P15056 | 12/20 | 0.84 |
| ▸ | KIT | P10721 | 1/20 | 0.56 |
| ▸ | FRK | P42685 | 1/20 | 0.56 |
| ▸ | SIK1 | P57059 | 1/20 | 0.56 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.56 |
| ▸ | SRMS | Q9H3Y6 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21046943 | 0.92 | BRAF (1.00) | MAP3K20BRAFKITFRKSIK1 | |
| SCHEMBL21046852 | 0.92 | MAP3K20 (0.84) | MAP3K20BRAF | |
| SCHEMBL29683373 | 0.92 | MAP3K20 (0.84) | MAP3K20BRAF | |
| SCHEMBL21047158 | 0.91 | BRAF (1.00) | MAP3K20BRAF | |
| SCHEMBL21046955 | 0.90 | BRAF (0.83) | MAP3K20BRAFKITFRKSIK1 | |
| SCHEMBL21046738 | 0.90 | BRAF (0.83) | MAP3K20BRAFKITFRKSIK1 | |
| SCHEMBL21048164 | 0.90 | MAP3K20 (0.81) | MAP3K20BRAF | |
| SCHEMBL21046898 | 0.89 | BRAF (0.86) | MAP3K20BRAFKITFRKSIK1 | |
| SCHEMBL21047261 | 0.89 | BRAF (0.82) | MAP3K20BRAFKITFRKSIK1 | |
| SCHEMBL21047190 | 0.89 | MAP3K20 (0.80) | MAP3K20BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3498693-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2024-10-30 | — | — | EP | disclosed |
| US-10696651-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-06-30 | — | — | US | disclosed |
| US-10696651-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-06-30 | — | — | US | disclosed |
| EP-3498693-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-06-19 | — | — | EP | disclosed |
| US-20190169166-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-06 | — | — | US | disclosed |
| US-20190169166-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696651-B2 | Heterocyclic compound | EIF2AK4, GCN1, GTF2I | MAP3K20 814/4885BRAF 1618/4885KIT 4717/4885 |
| US-20190169166-A1 | HETEROCYCLIC COMPOUND | EIF2AK4, GCN1, GTF2I | MAP3K20 814/4885BRAF 1618/4885KIT 4717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.